Unknown

Dataset Information

0

Serum- and glucocorticoid-induced kinase drives hepatic insulin resistance by directly inhibiting AMP-activated protein kinase.


ABSTRACT: A hallmark of type 2 diabetes (T2D) is hepatic resistance to insulin's glucose-lowering effects. The serum- and glucocorticoid-regulated family of protein kinases (SGK) is activated downstream of mechanistic target of rapamycin complex 2 (mTORC2) in response to insulin in parallel to AKT. Surprisingly, despite an identical substrate recognition motif to AKT, which drives insulin sensitivity, pathological accumulation of SGK1 drives insulin resistance. Liver-specific Sgk1-knockout (Sgk1Lko) mice display improved glucose tolerance and insulin sensitivity and are protected from hepatic steatosis when fed a high-fat diet. Sgk1 promotes insulin resistance by inactivating AMP-activated protein kinase (AMPK) via phosphorylation on inhibitory site AMPKαSer485/491. We demonstrate that SGK1 is dominant among SGK family kinases in regulation of insulin sensitivity, as Sgk1, Sgk2, and Sgk3 triple-knockout mice have similar increases in hepatic insulin sensitivity. In aggregate, these data suggest that targeting hepatic SGK1 may have therapeutic potential in T2D.

SUBMITTER: Zhou B 

PROVIDER: S-EPMC8576737 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3399766 | biostudies-literature
| S-EPMC10025096 | biostudies-literature
| S-EPMC3087946 | biostudies-literature
| S-EPMC3911293 | biostudies-literature
| S-EPMC9493433 | biostudies-literature
| S-EPMC2963531 | biostudies-literature
| S-EPMC6197624 | biostudies-literature
| S-EPMC4521589 | biostudies-literature
| S-EPMC373461 | biostudies-literature
| S-EPMC3330235 | biostudies-literature